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Breast cancer evolution and tumor progression are governed
by the complex interactions between steroid receptor [estro-
gen receptor (ER) and progesterone receptor] and growth
factor receptor signaling. In recent years, the field of cancer
therapy has witnessed the emergence of multiple strategies
targeting these specific cancer pathways and key molecules
(ER and growth factor receptors) to arrest tumor growth and
achieve tumor eradication; treatment success, however, has
varied and both de novo (up front) and acquired resistance
have proven a challenge. Recent studies of ER biology have
revealed new insights into ER action in breast cancer and
havehighlighted the role of an intimate crosstalk between the
ER andHER family signaling pathways as a fundamental con-
tributor to the development of resistance to endocrine ther-
apies against the ER pathway. The aim of this review article
is to summarize the current knowledge on mechanisms of
resistance of breast cancer cells to endocrine therapies due to
the crosstalk between the ER and the HER growth factor re-
ceptor signaling pathways and to explore new available ther-
apeutic strategies that could prolong duration of response
and circumvent endocrine resistant tumor growth. (Endo-
crine Reviews 29: 217–233, 2008)
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I. Introduction
BREAST CANCER EVOLUTION and progression aredeeply influenced by both estrogen receptor (ER) and
growth factor receptor signaling. In recent years, the field of
cancer therapy has witnessed the emergence of multiple
targeted strategies that inhibit specific key molecules and
pathways important for tumor growth and progression.
Among them, endocrine therapy to block ER activity and
signaling, the first targeted therapy in oncology, is still the
most successful systemic therapy in the management of ER-
positive breast cancer.
Tamoxifen, which binds to and antagonizes ER, has been
the mainstay of endocrine (hormonal) therapy in both early
and advanced breast cancer patients for almost three decades
(1, 2). Recently, its role has also expanded to preventive
therapy in patients at high risk of developing the disease (3).
Unfortunately, however, approximately 50% of patientswith
advanced disease do not respond to first line treatment with
the selective estrogen receptor modulator (SERM) tamoxifen
(de novo or up front, intrinsic resistance). Furthermore, almost
all patients with metastatic disease and many that receive
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tamoxifen as adjuvant therapy eventually experience tumor
relapse and die from their disease (acquired resistance).
Thus, de novo and acquired resistance to tamoxifen occur
frequently in breast cancer patients and seriously limit the
efficacy of this treatment.
Aromatase inhibitors (AIs) are a class of drugs that inhibit
the enzyme aromatase, which is responsible for converting
androgens (produced by women in the adrenal glands) to
estrogen, thereby lowering the circulating estrogen, and per-
haps the tumor levels of estrogen. By depriving ER of its
estrogen ligand (4–6), AIs inhibit tumor growth and are
proving superior to tamoxifen at least in certain patient sub-
sets (2, 7–9). However, the response rate to these compounds
is only slightly higher than the response rate to tamoxifen in
patients with advanced breast cancer, and both de novo (i.e.,
immediate) and acquired resistance after an initial response
commonly occur.
The membrane tyrosine kinase HER2 (c-ErbB2, HER2/
neu) is gene-amplified in 20–25% of ER-positive breast can-
cer (10). There is clinical evidence that tamoxifen is less
effective inHER2-positive tumors (11–13). Furthermore, pre-
clinical models show that HER2 overexpression can cause
tamoxifen-stimulated growth as a mechanism of de novo re-
sistance (14–17) and that the HER family receptors are also
implicated in acquired resistance to this drug (18). Advanced
studies of ER biology have revealed new insights into ER
action in breast cancer and have highlighted the role of an
intimate crosstalk between the ER and the epidermal growth
factor receptor (EGFR/HER1)/HER2 signaling pathways as
a fundamental contributor to the development of resistance
to endocrine therapies (19–21).
Accumulating knowledge of the mechanisms by which
breast cancer cells become resistant to endocrine therapy,
coupled with the availability of new compounds that can
interfere with the growth factor-driven signaling pathways
involved in resistance to endocrine therapy,might lead to the
development of new strategies for treatment of ER-positive
breast cancer patients (5). The aim of this review article is to
summarize the current knowledge on mechanisms of breast
cancer resistance to endocrine therapies, particularly those
that are due to the crosstalk between the ER and growth
factor receptor signaling pathways (focusing on the EGFR/
HER2 pathway), and to explore emerging therapeutic strat-
egies that prolong duration of response and circumvent en-
docrine resistant tumor growth.
II. Biology of the Estrogen Receptor (ER)
A. ER and ER subtypes
The ER signaling pathway and its estrogen ligands are
believed to be key players in the etiology and progression of
breast cancer. There are two different ER proteins, ER and
ER, that are produced by distinct genes. Whereas clinical
and experimental studies have confirmed the crucial role of
ER (22) in breast malignancies, the role of ER in breast
cancer is still controversial (23). Nonetheless, studies indicate
that ER can antagonize ER activity (24) and suggest that
reduced levels of ER protein are associated with resistance
to tamoxifen therapy (25). If not otherwise specified, “ER”
will refer to “ER” in the remainder of the manuscript.
B. Genomic action of ER
ER is mainly a nuclear protein that shares a common
structural and functional organization with many other nu-
clear receptors (22). Through its genomic nuclear activity,
also known as nuclear-initiated steroid signaling (NISS) (26),
ER functions as a ligand-dependent transcription factor and
promotes expression of a variety of genes (19). Many of these
gene products directly promote breast cancer cell prolifera-
tion and survival and tumor progression. Examples are the
IGF-I receptor (IGFR), the cell cycle regulator cyclin D1, the
antiapoptotic factor Bcl-2 (21, 27, 28), and the proangiogenic
vascular endothelial growth factor (20, 29). Nuclear ER also
induces the expression of different HER and other growth
factor receptor ligands including TGF and amphiregulin
(30), which are able to bind and activate EGFR (31). Recently,
microarray analysis of gene expression in the human breast
cancer ER-positiveMCF-7 cell lines suggests that in response
to estrogen, ER is also able to inhibit expression of a subclass
of genes (32), many of these being transcriptional repressors,
or genes with antiproliferative or proapoptotic function. The
ER protein is a composite of multiple domains including a
DNA-binding domain and two major transcriptional activa-
tion function (AF) domains, AF-1 and AF-2, which usually
act synergistically, although some gene promoters have been
shown to be activated independently by AF-1 or AF-2 (22,
33). The antineoplastic effects of endocrine therapeutic
agents are largely mediated by countering or eliminating the
transcriptional effects on gene expression of estrogen when
bound to ER.
Ligand binding to ER induces a specific conformational
change in the receptor, releases it from an inhibitory complex
consisting of several chaperone proteins (34), and triggers
receptor dimerization (34). This change further facilitates the
binding of coregulatory proteins (35) that alter ER transcrip-
tional activity on specific consensus DNA elements [also
known as estrogen response elements (EREs)], which are
present in the promoter regions of target genes (classic ac-
tion, Fig. 1A). In particular, the transcriptional activity of ER
is enhanced by the binding of coactivators such as members
of the p160 family of nuclear receptor coactivators [e.g., nu-
clear receptor coactivator 1 (NCoA1 or SRC-1), NCoA2 (SRC-
2), and NCoA3 (AIB1, SRC-3, TRAM1, RAC3, p/CIP or
ACTR) (36, 37) (Fig. 1A)]. These proteins lead to the forma-
tion of large complexes that enhance ER-driven transcription
by different mechanisms, including recruitment of histone-
acetyltransferases that modulate the chromatin structure at
the promoter site (36).
In contrast to estrogens, estrogen antagonists induce a
distinct receptor conformation leading to ER associationwith
corepressor complexes, such as nuclear-receptor corepressor
1 (NCoR1) and NCoR2 (SMRT), rather than with coactiva-
tors, thereby shutting off gene transcription (38, 39) (Fig. 1A).
Interestingly, SERMs, including tamoxifen and raloxifene,
havemixed agonist/antagonist activity andmay either stim-
ulate or antagonize ER function depending on the tissue, cell,
and gene context (40).
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Many coregulatory proteins may be present at rate-limit-
ing levels in the nucleus, so that changes in their level of
expression and/or activity can lead to alterations of ER sig-
naling. In particular, overexpression of coactivators and
down-regulation of corepressors can negate the inhibitory
effects of endocrine therapy, especially in the case of SERMs
(41–45). In this regard, recent studies have observed that
high AIB1 expression in patients who received tamoxifen
adjuvant therapy was associated with an inferior clinical
outcome, which is indicative of tamoxifen resistance (12, 46).
In addition to the “classical” mode of action of ER regu-
lating the expression of genes that harbor EREs in their pro-
moter region, ER can also regulate gene transcription atDNA
sites responsive to other transcription factors (40). Via this
so-called “nonclassical” mode, nuclear ER protein interacts
with other transcription factors such as specificity protein 1
(SP-1) and members of the Fos/Jun activating protein 1
(AP-1) transcription complex, leading to regulation of gene
expression at non-ERE regulatory DNA sequences (Fig. 1B)
(40, 47, 48).
Importantly, signaling from different growth factor recep-
tor-dependent kinases phosphorylates various factors in the
ER pathway, including ER itself; this potentiates ER genomic
signaling activity on gene transcription. As an example, ki-
nase-induced phosphorylation of nuclear ER on serine 305
(49–51) enhances cyclin D1 transcription in breast cancer.
Similarly, activation of the growth factor-dependent signal-
ing of p42/44 MAPK (ERK 1/2) and phosphatidyl inositol
3-kinase (PI3K)/AKT leads to an increase in ER serine 118
and serine 167 phosphorylation and ERAF-1 activity (52–54).
This phosphorylation of ER and its coregulatory proteins by
growth factor receptor-dependent kinases is an essential
component of the ordinary regulation and function of
genomic ER activity. However, in the presence of hyperac-
tive growth factor receptor signaling, as often occurs in breast
cancer (e.g., HER2 overexpression), an excessive phosphor-
ylation of ER and its coregulators may severely weaken the
inhibitory effects of various endocrine therapies and lead to
endocrine resistance, as will be detailed in Sections II and III
of this review.
C. Nongenomic rapid ER activity
Estrogen, as well as some SERMs like tamoxifen, has also
been shown to exert rapid stimulatory effects on a variety of
signal transduction pathways andmolecules. This rapid non-
genomic activity, also called MISS (for membrane-initiated
steroid signaling) (26), begins outside the nucleus and is
initially independent of gene transcription. The identity and
mode of function of the receptors responsible for this steroid-
induced rapid signaling are not completely clear at this point.
In the case of estrogen, however, it has been shown that this
activity is mediated, at least in part, by a small fraction of the
traditional ER protein or perhaps by its closely related short-
form splicing/translational variants (55–57) that are local-
ized near or at the plasmamembrane. Cytoplasmic signaling
molecules related to growth factor receptor signaling such as
the short form variant of metastasis associated gene 1 (17)
and themodulator of nongenomic action of estrogen receptor
(MNAR) (58) can increase this non-nuclear fraction of ER.
Molecular evidence suggests several mechanisms by which
non-nuclear/membrane or cytoplasmic ER couples with
components of signaling complexes and triggers their re-
sponses (59) (Fig. 2). Membrane ER may exist as a cytoplas-
mic pool tethered to the inner face of the plasma membrane
bilayer through binding to membrane proteins of lipid rafts
such as caveolin-1 (60, 61), flotillin-2 (62), or the caveolin-
binding protein striatin (63), or possibly through association
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FIG. 1. Nuclear genomic ER activity. ER, in its classical
action (A), directly binds to DNA sequences called estrogen
response elements (EREs) residing in the promoter region
of target genes, and by recruiting coregulatory proteins
regulates gene transcription. Estrogen (E2)-bound ER gen-
erally recruits coactivator (CoA) complexes to induce gene
transcription, whereas estrogen antagonists such as tamox-
ifen (Tam) mostly lead to ER association with corepressor
(CoR) complexes, thereby turning off gene transcription. In
its nonclassical action (B), ER regulates gene transcription
via protein-protein interaction (e.g., with Fos/Jun family
members) that tether ER to DNA sites responsive to other
transcription factors such as AP-1. Together, all of these
nuclear ER genomic activities also are called nuclear-
initiated steroid signaling (NISS).
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with other membrane receptors [e.g., IGFR (64), EGFR (65,
66), or HER2 (62, 67)], or with signaling adaptor molecules
such as Shc (64). Recent laboratory data further suggest that
the ER protein within isolated caveolar vesicles typically
spreads throughout the cell membrane in a similar fashion to
growth factor receptors (60, 68–70) and assembles as part of
a large signalsome complex that includes receptor tyrosine
kinases (EGFR, IGFR, HER2 receptor), nonreceptor tyrosine
kinases such as Src (71), and G proteins (68, 72, 73). Addi-
tional evidence from endothelial (56, 74) and breast cancer
(75) cell culture models suggests that estrogen-bound ER
coimmunoprecipitates with and/or activates distinct G pro-
tein subunits. These interactions trigger secondary down-
stream signaling pathways including effectors of p21Ras,
leading to activation of Raf/Mek/MAPK and of the AKT/
PI3K modules.
More detailed recent work has identified and defined mo-
tifs in a specific domain of ER that are critical to membrane
localization and function of the receptor (61, 76, 77). This
domain, also known as the E domain, resides in the carboxyl
(C) part of ER and harbors the ligand-binding domain and
AF-2 function. Mutations in these motifs prevent ER dimer-
ization, association with caveolin-1, and nongenomic ER sig-
naling to activate p42/44 MAPK, PI3K, and cAMP (76, 78).
Similarly, specific deletions at the caveolin-1 scaffolding do-
main largely prevent the localization of ER at the plasma
membrane (60, 76). Interestingly, however, ER interaction
with the signaling molecule MNAR involves both the amino
(N) terminus and portions of the E domain of ER (79). In
contrast, interaction of ER with Shc and striatin has been
reported to involve the N terminus of the receptor (64). ER
with deleted portions of its N terminus still localizes to the
membrane and signals to p42/44 MAPK equivalently to
wild-type ER (76), consistent with the idea that it is the E
domain at the C terminus of the receptor protein that con-
tains most of the information for both localization and func-
tion of ER at the membrane.
Studies in breast cancer culture models have shown that
the endogenous membrane ER can directly or indirectly ac-
tivate EGFR,HER2, and IGFR1 (80). This process involves the
sequential activation of the cellular tyrosine kinase Src (81),
matrix metalloproteinases (MMPs) 2 and 9, and the release
of the EGFR ligand heparin-binding epidermal growth
factor-like growth factor (HB-EGF), which, in turn, activates
the EGFR downstream kinase cascades (i.e., Ras/Mek/
MAPKandPI3K/AKT) (75, 76). These downstreamactivated
kinases, consequently, phosphorylate and thereby activate
ER and its coregulators, thus augmenting genomic activities
of ER on gene transcription (20, 52, 82) (Fig. 2). The genomic
and nongenomic mechanisms of action of ER, therefore, do
P
PCoA
ER
Transcription
P
P
CoA
TF
Transcription
TUMOR PROLIFERATION
ENDOCRINE RESISTANCE
Tam
N
MTA1s
c-Src
MNARPLC-PKC
-PKA
GP
MMPs
HB-EGF
EGFR/HER2
IGFR
GP
CR
E2
Tam
E2
GP
M
Cav
ER
ER
Cav
Shc
ER
ER
ER
MAPK / AKT
Phosphorylation signals
to the nucleus potentiate the
activity of genomic ER and other
TFs on gene regulation
GF
ER
Cav E2
Tam
FIG. 2. Integration of genomic and nongenomic/rapid ER signaling and its crosstalk with growth factor receptor and cell kinase pathways in
endocrine resistance: a working model. The ligand estrogen (E2) induces genomic ER activity in the nucleus (N), which results in increased
gene transcription, including important genes in the growth factor receptor pathways. The SERM tamoxifen (Tam) antagonizes this activity.
However, both estrogen and tamoxifen can turn on nongenomic signaling acting on ER that resides at the membrane (M) and/or cytoplasm (a
signaling mode also known as membrane-initiated steroid signaling, or MISS). This induction, in turn, through multiple interactions with
signaling intermediate molecules such as Shc and MNAR, can activate growth factor (GF) tyrosine kinase receptors (TKRs), such as EGFR and
HER2, and the IGFR and cellular kinases such as c-Src. Cytoplasmic signaling molecules such as metastasis-associated gene 1 (MTA1) can
increase this non-nuclear fraction of ER. The interaction between membrane/cytoplasmic ER and TKRs turns on the TKR pathways and their
downstreamkinases, e.g., p42/44MAPKandAKT.Other potentialMISS activity involves the activation, either directly or indirectly, of G protein
(GP)-coupled receptors (GPCRs), which can then trigger various signaling processes including the activation of c-Src andMMPs and subsequent
cleavage and release of HB-EGF. The HB-EGF can then stimulate and activate the EGFR/2 signaling pathway. TKR-induced kinases
phosphorylate (P) nuclear ER and its coactivators (CoA) as well as other transcription factors (TF), thus potentiating genomic ER activity, which
results in enhanced gene expression including genes in the TKR pathways. These gene products in turn further augment GF-TKR signaling,
thus completing the cooperative cycle between the two activities of ER and their crosstalk with the growth factor receptor and cellular kinase
pathways. In the presence of excessive TKR signaling, such as in HER2-overexpressing tumors, the nongenomic rapid ER action may become
more prominent. The resulting activation of downstream kinases can lead to endocrine resistance by modifying the activity of various
transcription factors and/or negating the inhibitory effects of tamoxifen on nuclear ER. PKA, Protein kinase A.
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not appear to be mutually exclusive, but rather are comple-
mentary to one another, and many interactions between
these two signaling forms exist. These two ER activities also
intimately interact at multiple levels with many cellular
(growth factor-dependent and other) kinase networks to sus-
tain bidirectional crosstalk that augments signaling of both
ER and kinase-related pathways.
In breast cancer, it is becoming evident that this crosstalk
of ER with the EGFR/HER2 pathway, and presumably with
additional growth factor receptor pathways, plays a very
important role not only in the physiological action of ER as
well as growth factor receptor signaling, but also in endo-
crine therapy resistance (42), as will be discussed in the next
section.
III. The HER Tyrosine Kinase Receptor Family and
Its Role in the Development of Endocrine Resistance:
Studies in Preclinical Models
As briefly discussed above, whereas the ER, via its mem-
brane and nuclear activities, up-regulates growth factor sig-
naling, the molecular crosstalk between these two pathways
is continuous and bidirectional. Signaling frommultiple sig-
nal transduction pathways can modulate both the genomic
and nongenomic activities of the ER pathway and their li-
gand dependency. In the section that follows, wewill discuss
in detail how this crosstalk, especially between the ER and
HER family, contributes to endocrine resistance.
A. HER/ER crosstalk as a mechanism for endocrine
therapy resistance: molecular determinants
Growth factor signaling plays an important role in the
development of both de novo and acquired resistance of
breast cancer cells to endocrine manipulation.
It has been demonstrated that ER can be phosphorylated
and activated by several intracellular kinases (42, 83). In
particular, ER is phosphorylated at key residues (including
serine 106/107, 118, 167, 305, and threonine 311) residing
mainly in the AF-1 domain, after p42/44MAPK, PI3K/AKT,
p90rsk, p21-activated kinase 1 Pak1, protein kinase A, or p38
MAPK pathway activation by various cytokines and growth
factors including ligands of EGFR or IGFR (42, 49–52, 54, 84).
ER phosphorylation has been shown to change ER pharma-
cology and can result in ligand-independent or tamoxifen-
mediated activation of the receptor (53, 54, 85). Phosphory-
lation of ER coregulators is probably no less important than
phosphorylation of ER itself in communicating these signal
transduction effects on the ER pathway. Phosphorylation of
coactivators, similarly to that of the receptor, enhances the
activity of the coactivators themselves on the genomic ER
even in the absence of its ligand or in the presence of an-
tiestrogens (42, 86). This phosphorylation potentiates the
ability of estrogen and SERMs to interact with ER and to
recruit other transcriptional coregulators to its transcrip-
tional complex (87); furthermore, it can directly activate their
intrinsic enzymatic activities (88). Phosphorylation of core-
pressors, on the other hand, can result in their export from
the nucleus, thereby preventing their access to and inhibition
of ER transcriptional complexes in the nucleus (89).
The ER coactivator AIB1 has been shown to be phosphor-
ylated and activated by multiple kinases including MAPKs
and other cellular kinases (86, 87, 90). Two independent
recent retrospective studies demonstrate that tumors with
high levels of both AIB1 and HER receptors (HER2 or HER3)
are less responsive to tamoxifen therapy, probably because
of increased estrogen agonistic activity of tamoxifen-bound
ER (12, 46). Such findings support the hypothesis that in-
creased signaling from theHER family activates downstream
kinases, which in turn activates ER and AIB1, increasing
transcriptional activity, including in the presence of
tamoxifen.
Finally, membrane functions of ER appear to depend not
only on ER, but also on the levels of growth factor receptors
and their ligands (14, 17). This mode of ER signaling might,
therefore, be predominant in breast cancer cells that express
high levels of tyrosine kinase receptors such as EGFR and
HER2 (Fig. 2). Importantly, it has also been suggested that
SERMs such as tamoxifen may behave as estrogen agonists
for these membrane effects of ER (14, 20).
B. HER2/ER crosstalk in de novo endocrine resistance
models
The involvement of HER2 in de novo resistance of breast
cancer cells to tamoxifen has long been hypothesized (67, 91).
In the BT474 HER2-overexpressing breast cancer model,
HER2 signaling has been shown to induce resistance to ta-
moxifen by inhibiting the apoptotic effects of the drug (15).
Most recently, using the MCF7/HER2–18 model, which is a
derivative line of MCF7 cells that stably overexpresses en-
dogenous AIB1 and exogenous HER2, Shou et al. (14) dem-
onstrated that in a low estrogen environment, tamoxifen acts
as a potent agonist on tumor growth. In both the above
HER2-positive breast cancer cell lines, both estrogen and
tamoxifen induce rapid (nongenomic) activation of EGFR/
HER2 signaling, which leads to activation of both p42/44
MAPK and AKT signal transduction pathways. These intra-
cellular kinases, as shown in the MCF7/HER2–18 cells, then
phosphorylate and functionally activate both ER and the
coactivator AIB1. Furthermore, culture of these MCF-7/
HER2–18 cells under short-term tamoxifen treatment in-
creases the expression of estrogen-regulated genes nearly as
well as estradiol itself. This phenomenon is due to the ability
of tamoxifen-ER complexes to recruit coactivators such as
AIB1 rather than corepressors to ER-targeted promoters in
these HER2-overexpressing cells. Interestingly, all of these
phenomena could be blocked by treatment with the selective
EGFR-tyrosine kinase inhibitor (TKI) gefitinib (Iressa;
AstraZeneca, Macclesfield, Cheshire, UK), which can block
signaling from EGFR/HER2 heterodimers, suggesting that
EGFR/HER2 signaling is directly involved in the growth-
promoting activity of tamoxifen in HER2-overexpressing
cells. In this respect, gefitinib was highly effective in inhib-
iting the tamoxifen-induced growth of MCF-7/HER2–18
cells, whereas it had only a modest effect on estrogen-in-
duced growth (14). The above-mentioned findings are in
agreement with the clinical observations noted earlier indi-
cating that tumors that coexpress HER2 and AIB1 have poor
outcome when treated with tamoxifen (12, 46).
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C. HER2/ER crosstalk in acquired endocrine resistance
models
Recent laboratory and clinical studies have shown that
acquired resistance to tamoxifen in tumors that originally
express low levels of EGFR and HER2 is also associated with
increased EGFR/HER2 signaling, including HER2 gene am-
plification (92, 93). Experimental evidence by Nicholson and
Gee’s group (94) has demonstrated that EGFR/HER2 sig-
naling is involved in acquired tamoxifen resistance of breast
cancer cells in long-term culture. These cells show increased
levels of expression of EGFR and HER2, increased activation
of EGFR/HER2 heterodimers, and increased phosphoryla-
tion of p42/44 MAPK, AKT, and nuclear ER (on serine res-
idues 118 and 167) (95, 96). As in the de novo experimental
models of tamoxifen resistance, the growth of these cells after
acquiring resistance is significantly inhibited by treatment
with the EGFR/HER2 inhibitor gefitinib or the monoclonal
anti-HER2 antibody trastuzumab (Herceptin; Genentech,
Inc., South San Francisco, CA) (96, 97). Another tyrosine
kinase receptor, the IGFR, has also been associated with
tamoxifen resistance. In fact, it has recently been reported
that IGF-II treatment activates both IGFR and EGFR/HER2
in tamoxifen-resistant cells (98). Taken together, these find-
ings suggest that enhanced growth factor signaling, which
up-regulates both the genomic and nongenomic activities of
ER, is a key contributor to the mechanism of acquired re-
sistance to tamoxifen.
Enhanced expression of EGFR and HER2, together with
subsequent downstream activation of signaling pathways
regulated by p42/44 MAPK, has also been identified in
breast cancer cell models that have become resistant over
time to estrogen depletion or to AI therapy (99–101). Inter-
estingly, MCF-7 cells adapted to grow in the presence of the
potent antiestrogen fulvestrant also show increased EGFR
signaling, suggesting that growth factor receptors play cen-
tral roles in resistance to various endocrine therapies such as
AIs and pure ER antagonists in addition to tamoxifen (94,
102, 103).
IV. The HER Tyrosine Kinase Receptor Family and
Its Role in the Development of Endocrine Resistance:
Clinical Evidence
A. De novo endocrine resistance
Cumulative clinical data suggest that patients with HER2-
and EGFR-overexpressing tumors have a poorer outcome
when treated with tamoxifen (13, 104, 105). In a subset of
patients with metastatic breast cancer, results of published
studies have been somewhat inconsistent due to different
study designs, different techniques formeasuringHER2, and
the relatively small numbers of patients included in each
study. Despite this heterogeneity, a recently publishedmeta-
analysis examining the interaction betweenHER2 expression
and response to endocrine treatment in metastatic disease
clearly shows that HER2-positive breast cancer is less re-
sponsive to endocrine treatment (13). EGFR generates sim-
ilar, although not identical, downstream signals as HER2. In
metastatic breast cancer patients, EGFR overexpression is
also predictive of a decreased benefit from tamoxifen (18,
106). In a recent study (104), tumors with higher EGFR were
less likely to respond to tamoxifen, and these patients had a
significantly shorter time to treatment failure. Evenwhen ER
and progesterone receptor (PgR) levels were taken into con-
sideration, EGFR remained predictive of a less sustained
response, supporting the hypothesis that signaling from
otherHER familymembers besidesHER2 can also contribute
to the development of tamoxifen resistance.
In patientswith early breast cancer, several studies suggest
that patients with tumors overexpressing HER2 may derive
less benefit from adjuvant tamoxifen than those with HER2-
negative tumors (107) and that HER2 expression is a risk
factor for tamoxifen failure (108). However, this is not a
universal finding, probably because in many adjuvant stud-
ies chemotherapy use may have obscured the interaction
(109, 110). The difficulty in making a conclusive judgment is
illustrated by data from the collection of samples from the
NATO and Cancer Research Campaign adjuvant breast can-
cer trials with 2 yr of tamoxifen vs. no treatment (111). In this
study, the relative risk of recurrence for tamoxifen was 0.54
for patients negative for both HER2 and EGFR and 1.17 for
HER2-positive and/or EGFR-positive patients. However,
despite the big difference in the relative risk of recurrence
between the different patient groups and the more than 800
patients in the study overall, the small size of the EGFR-/
HER2-positive tumor group resulted in se estimates that
overlapped with those of the HER-negative population. A
positive association between overexpression of HER family
receptors (EGFR and/orHER2 and/orHER3) and tamoxifen
outcome has recently been shown in two additional inde-
pendent datasets of patients treatedwith adjuvant tamoxifen
(112, 113).
At present there are no clear outcome data related toHER2
status from adjuvant trials of AIs. Data on the influence of
HER2 status on the relative benefits of tamoxifen and the AI
letrozole as adjuvant therapy in the Breast International
Group (BIG) 1-98 trial (114, 115) are, therefore, of consider-
able interest. Both preliminary and updated reports indi-
cated that HER2-positive status was associated with signif-
icantly higher relapse rate in the BIG 1-98 trial, regardless of
whether letrozole or tamoxifen was used. Additional studies
are currently underway to determine the significance of
HER2 status in the large randomized adjuvantATAC (Arimi-
dex, Tamoxifen, alone or in combination) trial comparing the
AI anastrozole, the SERM tamoxifen, and the combination
(116).
Neoadjuvant trials conducted in women with locally ad-
vanced breast cancer before surgery provide a unique op-
portunity to integrate the molecular determinants of re-
sponse and resistance with the clinical response of primary
breast cancer to medical therapy. Results in the neoadjuvant
setting are less controversial and provide solid evidence for
the role of HER2 and to a lesser extent of EGFR in tamoxifen
resistance (Table 1). Ellis et al. (117), in a neoadjuvant study
that randomized for treatment with the AI letrozole vs. ta-
moxifen, provided a context to study in further detail the
relationship between EGFR and HER2 expression and re-
sponse to AIs vs. tamoxifen. In this report, biopsy-confirmed
ER-positive and/or PgR-positive cases that received letro-
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zole had a statistically significant better response rate com-
pared with those receiving tamoxifen (60 vs. 41%, respec-
tively). In retrospective analysis, differences in response rates
between the twodrugsweremostmarked for the ER-positive
tumors that were also positive for EGFR and/orHER2 (88 vs.
21%), suggesting that EGFR and HER2 signaling through ER
is ligand-dependent (estrogen or tamoxifen) and that the
growth-promoting effects of these receptor tyrosine kinases
on ER-positive breast cancer can be inhibited by potent es-
trogen deprivation therapy.
In a different neoadjuvant study in locally advanced breast
cancer patients, Zhu et al. (118) analyzed levels of HER2
expression before and after AI treatment and correlated them
to the clinical outcome of patients. Using both immunohis-
tochemistry and fluorescence in situ hybridization (FISH),
data from this study showed that response to the treatment
was significantly influenced byHER2 status, with a response
rate of 75% for HER2-positive and 35% for HER2-negative
tumors (P  0.017). In addition, the response rate was also
significantly affected by the decrease inHER2 status after the
treatment, with a response rate of 73% for tumors showing
decreased HER2 overexpression and 38% for tumors show-
ing no change in HER2 expression (P  0.037).
Most recently, Smith and associates (11, 107) carried out a
series of biomarker studies in the IMPACT neoadjuvant trial,
a double-blind study that randomized 330 patients to
3-month treatment with the AI anastrozole or tamoxifen or
a combination of the two agents. The primary marker of
biological efficacy in this study was the nuclear proliferation
antigen Ki67 (119). Of particular importance, it was shown
that suppression of Ki67 was greater at both 2- and 12-wk
timepoints when using anastrozole compared with either
tamoxifen or the combination, confirming the results ob-
tained in the earlier ATAC trial (7) in which the superiority
of anastrazole over both tamoxifen and the combination was
also demonstrated. This study indicates that analysis of Ki67
may be considered a useful marker of early response or
resistance to endocrine agents. Further subanalysis of the
IMPACT study investigated the effect of ER, PgR, and HER2
on the antiproliferative effects of, and the clinical response to,
the agents. Only four patients were EGFR-positive and ER-
positive, so the analysis was confined to the 34 patients who
were both HER2- and ER-positive. Seven of 12 (58%) HER2-
positive patients responded to anastrazole compared with
two of nine (22%, P 0.09) to tamoxifen and four of 13 (31%)
to the combination (11). In the HER2-negative population,
responses were 28 of 68 (41%) for anastrazole, 31 of 73 (43%)
for tamoxifen, and 33 of 64 (52%) for the combination. Thus,
although the numbers of patients are small in this subgroup
analysis, in the HER2-positive group, the data tend to sup-
port the findings of the letrozole study (117). RegardingKi67,
in the overall population, there was marginally greater Ki67
suppression in the HER2-negative group than in the HER2-
positive group after 2 wk, and this difference seemed to be
confined to the group treatedwith tamoxifen (120). At 12wk,
there was a statistically significant greater suppression by
anastrazole of Ki67 in the HER2-negative group compared
with the HER2-positive group: mean Ki67 suppression in the
HER2-positive group was 45% and in the HER2-negative
group was 85%. This contrasts with the good clinical re-
sponse witnessed in this small HER2-positive group of pa-
tients and may suggest that resistance dependent on HER2
signaling might rapidly emerge as was reported in a recent
preclinical model (102). Furthermore, a recent follow-up re-
port by Ellis et al. (121) also supports the idea that in ER-
positive, HER2-positive tumors, estrogen-independent sig-
naling that leads to increased proliferation is present even
during therapywithAIs. Therefore, in such tumors, although
estrogen deprivation may be highly effective initially, the
addition of HER signaling inhibitors may be needed for a
sustained response.
B. Progesterone receptor (PgR) negativity associated with
endocrine resistance and HER signaling
Progesterone regulates cell growth in normal breast tissue
and in the uterus. The PgR, which is transcriptionally up-
regulated as a downstream effect of activated ER, plays an
important role in mammary growth and development, es-
pecially during pregnancy. Its role in breast cancer is some-
what less established than that of ER, but epidemiological,
experimental, clinical, and molecular data suggest that PgR
signaling plays a critical role in breast cancer development
and progression (122–126). Numerous studies have identi-
fied different mechanisms of PgR activation resembling ER
signaling, including ligand-dependent and ligand-indepen-
dent activation (124–127). Ligand-dependent action is based
on PgR functioning as a classical ligand-activated transcrip-
tion factor in the nucleus (genomic action), and PgR can
up-regulate the expression of various genes involved in cell
proliferation, survival, and tumor progression, including cy-
clin D1, Bcl2, and vascular endothelial growth factor. Pro-
gesterone action is also based on PgR activating p42/44
MAPK pathways by direct interaction with c-Src-family ty-
rosine kinases, an event that requires progesterone binding
to PgR and occurs in the cytoplasm and/or in association
with cell membranes (nongenomic orMISS action) (124, 127).
Intriguing preclinical and clinical studies have recently
suggested that PgR negativity in ER-positive breast cancer
may be amarker of hyperactive growth factor signaling (128)
rather than a result of a nonfunctional ER signaling pathway,
as previously suggested (129). Recent laboratory studies sug-
gest that growth factors in the IGF and EGF families that
activate the PI3K-AKT-mTOR (mammalian target of Rapa-
mycin) pathway can reduce expression of PgR at its tran-
scriptional (mRNA) level (129). Alternatively, studies from
TABLE 1. Response to estrogen deprivation/SERMs in the neoadjuvant setting
Study 1 Ellis (117) Study 2 Zhu (118) Study 3 Smith (11)
Letrozole Tamoxifen Letrozole Tamoxifen Letrozole Tamoxifen
EGFR/HER2 negative 54% 42% 35% – 41% 43%
EGFR/HER2 positive 88% 21% 75% – 58% 22%
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Lange et al. (130, 131) have demonstrated a coupling between
transcriptional hyperactivity of PgR and increased PgR pro-
tein turnover. Accordingly, HER downstream kinases, such
as p42/44 MAPK and cyclin-dependent kinase 2, which
phosphorylate PgR and its accessory proteins and dramat-
ically increase PgR transcriptional activity including in the
presence of low levels of progesterone, also greatly increase
PgR turnover, resulting in PgR-low or PgR-negative tumors
(128, 129, 132–135). Finally, increased ligand-independent
activation and transcriptional hypersensitivity of PgR asso-
ciated with breast cancer cell growth have also been recog-
nized as deriving from the phosphorylation of PgR under
EGFR/EGF signaling (134).
Thesemolecular data, in concert with clinical findings that
follow, suggest that loss of PgR expression in some tumors,
at the mRNA and/or the protein level, may be due to in-
creased growth factor receptor activity potentially leading to
endocrine therapeutic resistance. Although more studies are
needed on this topic, these results suggest that suppressed/
reduced PgR levels may derive from and indicate hyperac-
tivity in the signaling cascade generated byEGFR,HER2, and
other kinase activation.
Studies in the clinical setting in patients with metastatic
breast cancer indicate that PgR is a predictive factor for the
outcome of endocrine therapy (136). However, there is still
no definitive evidence on the predictive role of PgR in
women with early breast cancer receiving adjuvant endo-
crine therapy. The overview data from 2005 (137) shows a
41% reduction in recurrence in ER-positive, PgR-poor pa-
tients receiving about 5 yr of tamoxifen comparedwith a 40%
reduction in the ER-positive, PgR-positive patients. This sug-
gests that there is no underperformance of tamoxifen in
ER-positive, PgR-negative patients, although this data set
originally suggested benefit from tamoxifen in patients with
ER-negative tumors, raising questions about receptor assay
quality. The overview data conflict with those from a large,
albeit nonrandomized series, where biochemical ER and PgR
assays were identically performed in two different central
laboratories and in which benefit from tamoxifen was sub-
stantially less in PgR-negative tumors (138).
Many clinical studies have confirmed in both metastatic
and early breast cancer that the benefit of tamoxifen is less
in ER-positive/PgR-negative vs. ER-positive/PgR-posi-
tive tumors (138–142). A retrospective analysis from the
ATAC trial showed that patients with ER-positive/PgR-
positive tumors had a lower recurrence rate than those
with ER-positive/PgR-negative tumors (7.6 vs. 14.8%)
(143, 144). This difference, however, was largely due to the
reduced efficacy of tamoxifen in the subgroup of patients
with ER-positive/PgR-negative tumors. In contrast, there
was little difference in the recurrence rate with anastrozole
in the PgR-positive vs. PgR-negative subsets. The obser-
vation that patients with ER-positive/PgR-negative tu-
mors respond nearly as well to the AI as those with PgR-
positive tumors suggests that the ER signaling pathway is
functional in many ER-positive/PgR-negative tumors and
that these tumors are still dependent on estrogen for
growth despite somewhat lower ER levels. Importantly
however, a recently updated conference report of this trial,
analyzing the differential response of PgR-negative tu-
mors to AIs vs. tamoxifen only in specimens with centrally
reviewed steroid receptor expression, failed to confirm the
selective benefit of AIs vs. tamoxifen in this group of
tumors. A worse outcome was, nonetheless, demonstrated
in patients with PgR-negative tumors, regardless of the
endocrine therapy used (145). A similar interaction be-
tween PgR-negative status and endocrine resistance in the
adjuvant tamoxifen setting was also found in a recent
study in an independent group of patients (112). Finally,
a report from the BIG 1-98 trial that compared letrozole
and tamoxifen with sequences of each agent, while con-
firming the finding that patients with PgR-negative tu-
mors have a worse clinical outcome, failed to demonstrate
an effect of PgR expression on the relative efficacy of
letrozole over tamoxifen (114). Whether PgR negativity is
a predictive factor for poor clinical outcome on endocrine
therapy or a prognostic factor, as recently suggested by
RT-PCR-based assays (146), remains controversial and
needs to be further investigated.
A recent retrospective analysis from Arpino et al. (147)
considered a large number of patients with tumor receptor
assays all performed centrally by standardized tech-
niques; this work provides clues to the origin of the dis-
tinct ER-positive/PgR-negative phenotype. PgR-negative
tumors have more aggressive features: they are larger,
have more nodal metastases, are more likely to be aneu-
ploid, and are more rapidly proliferating. Interestingly,
PgR-negative tumors are also associated with a signifi-
cantly higher frequency of HER2 overexpression and high
expression of EGFR. About 30% of ER-positive, PgR-neg-
ative tumors are HER2- and/or EGFR-positive compared
with only 10% of ER-positive, PgR-positive tumors (147).
As indicated in the preclinical setting, several recent clin-
ical reports also suggest that high growth factor receptor
activity may be associated with reduced PgR levels in
breast cancer (148–151). For example, tamoxifen-treated
women with ER-positive/PgR-negative and either EGFR
or HER2-positive tumors are found to have a significantly
worse outcome than patients in the same subgroup whose
tumors display low EGFR orHER2. In contrast, deleterious
effects of high EGFR or HER2 are less apparent in patients
with ER-positive/PgR-positive tumors (147) (Fig. 3). One
possible explanation is that less active EGFR and HER2
signaling despite receptor overexpression occurs in ER-
positive/PgR-positive tumors and results in a smaller im-
pact on response to tamoxifen. In this context, PgR loss
may be amarker of active EGFR/HER2 signaling networks
in these HER2-positive tumors.
C. HER2/ER crosstalk in acquired endocrine resistance
Recent provocative clinical studies document that acquired
resistance to tamoxifenmay also be associatedwith an increase
in HER2 expression and/or gene amplification as shown in
preclinical models. One study analyzed the changes in growth
factor receptors and their associated downstream kinases in
tumors after the development of tamoxifen resistance (92). A
tissue microarray was constructed of pairs of samples from the
same patient, first at presentation, and second at the develop-
ment of tamoxifen resistance during adjuvant therapy. A total
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of 39 patients had sufficient tissue in both samples on the arrays
to provide near-complete sets of data. Pretreatment, strong
positive correlations between ER, PgR, and Bcl-2, and an in-
verse correlation between ER and HER2, were found as ex-
pected. These correlations were lost in the tamoxifen-resistant
tumors and replaced by strong correlations between ER and
phosphorylated (p) p38 MAPK (p-p38) and phosphorylated
p42/44 MAPK (p-p42/44 MAPK). ER expression was lost in
17%of resistant tumors. Three (11%) of the 26 tumors originally
negative for HER2 became amplified and/or overexpressed at
resistance. All ER-positive tumors that overexpressed HER2
originally or at resistance expressed high levels of p-p38. In the
pretreatment and tamoxifen-resistant specimens, there were
strong correlationsbetweenp-p38 andp-p42/44MAPK.There-
fore, themolecular pathwaysdriving tumor growth can change
as the tumor progresses, and the HER family may play an
important role in the development of acquired tamoxifen
resistance.
Acquired HER2 gene amplification during cancer progres-
sion after tamoxifen adjuvant therapy has also been recently
reported in patients’ circulating tumor cells (93). Similarly, se-
rum HER2 conversion from negative to positive has also been
shown in patients with advanced disease at the time of disease
progressiononendocrine therapy (152). Thesedata suggest that
acquired HER2 overexpression can occur during endocrine
treatment, perhaps as an adaptive mechanism for tumor cell
survival on these therapies or as a consequence of reversing
ER-induced down-regulation of HER expression by endocrine
therapy (152).
At present, there are no biological data on samples de-
rived at relapse from patients on AIs. This is an area of
substantial clinical importance over the next few years,
because these agents are more frequently used in the ad-
juvant setting. Sampling tumors for molecular studies be-
fore and after treatment will enhance our understanding
of the mechanisms of response and resistance to these
therapies (11, 116).
V. Novel Therapeutic Strategies to Overcome
HER/ER Pathway Crosstalk and Endocrine
Resistance
A. Preclinical studies
Treatment with various growth factor receptor inhibitors
and other signal transduction inhibitors (STIs) has been used
in preclinical tumor models as an attempt to block growth
factor signaling pathways (96, 153–156). However, several
reports have shown that in hormone-sensitive, ER-positive
breast cancer, these inhibitors as monotherapy (used one at
a time) may have only a minimal effect on tumor growth (14,
102, 157, 158). As discussed above, during prolonged endo-
crine therapy, adaptative changes occur such as up-regula-
tion of growth factor signaling (96, 153–156), whichmay lead
to endocrine resistance. Thus, strategies to combine endo-
crine therapies with STIs against growth factor receptor
downstream signaling molecules such as farnesyltransferase
inhibitors (directed against the Ras signaling pathway) and
mTOR inhibitors (159, 160), have been used in hopes of
preventing resistance and improving therapeutic efficacy of
endocrine agents (83).
In vitro, the combination of tamoxifen and the selective
EGFR TKI gefitinib provided nearly complete inhibition of
p42/44 MAPK and AKT phosphorylation, greater suppres-
sion of the cell-survival protein Bcl-2, and more complete
G0/G1 cell-cycle arrest than that observed with tamoxifen
alone (97). In particular, this combined therapy prevented
acquired EGFR/p42/44 MAPK signaling and significantly
delayed the subsequent resistance that started to develop
after 5 wk in tamoxifen-alone-treated cells. For de novo ta-
moxifen-resistant breast cancermodelsmade by stable trans-
fection ofHER2, the strategy of combining endocrine therapy
with different HER inhibitors or other STIs is also more
effective than using either therapy alone (14, 154, 157). A
synergistic effect has also been reported for the anti-HER2
antibody trastuzumab combined with tamoxifen in ER-pos-
itive, endogenously HER2-positive BT474 breast cancer cells,
A B
C D
FIG. 3. Kaplan-Meier curves for disease-free survival
(DFS) in tamoxifen-treated patients according to the
HER family receptor and PgR status. Among tamoxifen-
treated patients with ER/PR tumors, neither EGFR
(HER1) nor HER2 had a significant effect on DFS, al-
though there was a suggestion of a trend in HER2-pos-
itive tumors. In contrast, among patients whose tumors
were ER/PR, both EGFR and HER2 expression were
associated with significantly poorer DFS (for HER-1,
HR  2.4, 95% CI  1.0 to 5.4, P  0.04; and for HER2,
HR 2.6, 95% CI 1.1 to 6.0, P 0.03). [Adapted with
permission of Oxford University Press fromArpino et al.
(147).]
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with enhanced accumulation of cells in G0/G1 and a reduc-
tion in S-phase compared with either therapy alone (161).
Recently, the dual EGFR/HER2 TKI lapatinib (Tykerb,
GW57016; GlaxoSmithKline, Brentford, UK) has been shown
to cooperate with tamoxifen and other endocrine agents to
provide more rapid and profound cell-cycle arrest than ei-
ther therapy alone in endocrine-resistant cells (162, 163).
In vivo, it has been shown that gefitinib added to tamoxifen
can completely overcome the agonist activity of tamoxifen
and significantly delay the growth of stably transfected
HER2-positive MCF-7 xenografts (14). Similar beneficial ef-
fects were seen with gefitinib combined with estrogen de-
privation. The combination more effectively inhibited
growth and delayed the acquired resistance that develops
rapidly with estrogen deprivation alone (102).
Finally, data from amore recent study (157) demonstrated
in both MCF7/HER2–18 and BT474 ER-positive, HER2-pos-
itive xenograft tumors that a combination of several HER
inhibitors designed to completely inhibit signaling from all
HER dimer pairs, together with, where applicable (MCF7-
HER2–18), either tamoxifen or estrogen deprivation, is much
more effective in inducing apoptosis and slowing prolifer-
ation than each individual drug. Multidrug anti-HER com-
binations such as those used in the above study can com-
pletely eradicate tumors in a substantial number of mice.
These provocative data suggest that one type of resistance to
the HER inhibitors used currently in the clinic is incomplete
blockade of downstream signals generated by the various
homo- and heterodimers of theHER family, and also suggest
that tumors, to survive, can switch or use an alternative HER
dimer pathway when the pathway being used by the cells is
blocked. Importantly, however, in one of the above two
ER-positive, HER2-positive xenograft models, this potent
combination anti-HER therapy was only modestly effective
when implemented without endocrine therapy, supporting
the concept that initial complete blockade of all HER dimer
pairs, together with ER blockade, may be necessary for op-
timal treatment in some breast tumors.
B. Clinical studies
Taken together, the experimental data indicate that vari-
ous growth factor receptor and other intracellular signaling
pathways may be activated or overexpressed in breast can-
cer, especially in endocrine-resistant cells, and suggest that
targeting such pathways simultaneously with the ER path-
way may be an effective therapy.
Proof of principle for therapies that specifically target
growth factor pathways in breast cancer has already been
provided with the HER2 monoclonal antibody trastuzumab
(Herceptin). Successful clinical use of trastuzumab has been
demonstrated in HER2-positive breast cancer, and signifi-
cant activity has been seen as first-linemonotherapy, with up
to a 48% clinical benefit rate in HER2-positive tumors and a
34% objective response rate in tumors reported positive for
HER2 amplification by fluorescence in situ hybridization
(164). Thus, it is hoped that various small molecule TKIs and
STIs might also prove effective anticancer strategies in the
appropriate setting. Early phase II clinical studies have been
initiated with EGFR/HER2 TKIs, farnesyltransferase inhib-
itors, and more recently mTOR antagonists, as monotherapy
in patients with advanced (often heavily pretreated) disease;
such studies, however, have been somewhat disappointing,
with low clinical response rates and rapid disease progres-
sion (83).
The EGFR inhibitor gefitinib, an orally active, low-molec-
ular-weight, selective EGFR-TKI, has been studied in pa-
tients with breast cancer. There have been several phase II
monotherapy studies of gefitinib in patients with advanced
breast cancer (165–167). Overall, the data are relatively dis-
appointing. The only trial in the metastatic setting to report
a significant number of responses includes patients with
ER-positive tumors progressing on tamoxifen (167), a setting
in which preclinical models have shown the best evidence of
activity for gefitinib. Pharmacodynamic studies performed
in one of these trials confirmed that EGFR tyrosine kinase
signaling is inhibited in both skin and tumor biopsies by the
doses of gefitinib delivered orally (166). However, discor-
dance in the effect of gefitinib on downstream intracellular
signaling in treated tumor biopsies has been noted, with lack
of inhibition of Ki67 in tumors but not in matched skin
biopsies. This suggests that activation of other intracellular
pathways downstream of EGFR (especially in breast cancer
as opposed to normal skin cells) may determine the clinical
response to gefitinib. More research is required to establish
tumor phenotypes and specific predictive biomarkers in re-
sponding vs. nonresponding patients (168). Indeed, a recent
neoadjuvant trial that randomized ER-positive, EGFR-posi-
tive patients to gefitinib plus theAI anastrazole or to gefitinib
alone (169) demonstrated greater reduction in Ki67 with the
combination. Fewer clinical data exist regarding other EGFR-
TKIs in breast cancer, although a phase II monotherapy trial
of the selective EGFR TKI erlotinib (OSI-774) in breast cancer
has proven relatively disappointing (170).
As mentioned above, cooperative activation of different
growth factor receptors, and especially between HER recep-
tors (EGFR/HER1-HER4), may limit the efficacy of targeting
just one single receptor (157). Lapatinib is a potent dual
inhibitor of both EGFR and HER2 and blocks autophosphor-
ylation of both receptors (171–173). As noted above, it was
effective with tamoxifen in cell culture studies of hormone-
resistant cells (162, 163, 171). In phase I/II clinical studies,
clinical activity was reported in heavily pretreated patients
with EGFR-positive and/or HER2-posistive tumors and in
trastuzumab-resistant breast cancer patients (172–175), and
diarrhea and skin rash were the main toxicities. Several bi-
ological and pharmacological reasons may account for the
efficacy of a small molecule inhibitor of HER2 in patients
resistant to therapy with trastuzumab. A phase II trial of
lapatinib has been completed in heavily pretreated patients
with advanced breast cancer that progressed on prior tras-
tuzumab-containing regimens. A recent analysis of the first
41 patients confirmed clinical activity for lapatinib in breast
cancer, with partial response in 7% of patients and/or stable
disease in 24% of patients after 16 wk of therapy (174).
Based on the preclinical and clinical evidence suggesting
benefit, several phase II/III trials have been initiated with
TKIs or monoclonal antibodies in combination with tamox-
ifen, fulvestrant, or AIs (Table 2). Some of these trials are in
the second-line setting, including patients whose tumors
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were progressing on tamoxifen, and then lapatinib was
added to tamoxifen to see whether clinical responses could
be observed and resistance reversed. The majority, however,
are randomized phase II studies with only 100–200 patients,
and in some studies the primary efficacy endpoint is objec-
tive response rate rather than time to progression. Such stud-
ies are asking whether the combination may provide greater
initial antineoplastic activity than endocrine therapy alone,
expecting to enhance or restore the response in tumors with
de novo endocrine resistance. However, given the preclinical
data, prolongation of time to progression (i.e., delaying re-
sistance onset) rather than response rate might be a better
endpoint for these trials.
The first safety and efficacy data for the combination of an
AI (letrozole) with trastuzumab for the treatment of ER
and/or PgR-positive and HER2-positive advanced breast
cancer have recently been published (176). In this study,
although the response rate to the combination of trastu-
zumab plus letrozole was not enhanced over trastuzumab
monotherapy from previous data, the responses were more
durable. Further phase III studies that compare letrozole
alone vs. trastuzumab alone vs. the combination will be nec-
essary to fully outline the efficacy of the combination regi-
men. In addition, results from an open label phase III trial
evaluating the safety and efficacy of trastuzumab plus anas-
trazole vs. anastrazole alone, demonstrated that trastuzumab
prolonged progression-free survival in hormone-depen-
dent/HER2-positive metastatic breast cancer (177).
Recently, a randomized phase II neoadjuvant trial of anas-
trazole gefitinib explored whether the AI gefitinib com-
binationmight improve clinical outcome (178). The results of
this trial were disappointing in that there was no significant
difference in biological or clinical outcomes between the two
treatment arms. In fact, there was a nonsignificant trend in
response rate favoring the AI alone instead of the combina-
tion (response rate, anastrazole 61%, vs. anastrazole  ge-
fitinib 48%; P  0.067) (169, 178). Whether this result might
be different in patients selected for EGFR or HER2 overex-
pression remains to be seen in other studies. The results of
the aforementioned trial (169), which demonstrated greater
suppression of Ki67 by the addition of AI therapy to the
EGFR inhibitor gefitinib in patients with ER-positive/EGFR-
positive breast cancer, strongly supports this concept. A large
randomized phase III trial comparing the dual EGFR and
HER2 inhibitor lapatinib with or without letrozole in ER-
positive advanced metastatic breast cancer is currently on-
going. Again, the recently published preclinical data show-
ing the ability of lapatinib to reverse hormone resistance and
to cooperate with tamoxifen in providing maximal growth
arrest provide the rationale for this study (162).
It will be important in all of the trials mentioned in Table
2 and similar other studies to stratify for prior endocrine
therapy (usually tamoxifen) given in the adjuvant setting
and, in particular, the interval since completion of such
therapy. This is important because it may have implica-
tions for the presence or absence of activated growth factor
signaling in the relapsed tumor, which could determine
the efficacy of added gefitinib or lapatinib. In addition,
biological studies are required to help predict those pa-
tients who are more likely to benefit from combined en-
docrine/anti-HER therapy. For example, the tamoxifen/
gefitinib trial (Table 2) will undertake studies to look at
downstream intracellular signaling components of the
HER family, in addition to assessment of ER and ER co-
activators such as AIB1.
VI. Future Challenges
As the complexity of ER biology is being revealed, so is the
complexity of themechanisms responsible for endocrine sen-
TABLE 2. Selected recent ongoing and completed phase II/III clinical trials of inhibitors of HER family receptors in combination with
endocrine therapy
Trial design Disease setting Trial phase Primary endpoints Outcomes
Gefitinib
Tamoxifen  gefitinib Metastatic II RCT TTP Completed
Anastrazole  gefitinib (178) Neoadjuvant II RCT ORR NS ORR favoring the AI alone instead of the
combination
Gefitinib  anastrazole (169)a Neoadjuvant II RCT 2 Ki67 labeling index 2 Ki67 labeling index 98% vs. 92.4%
2 in tumor size 2 in tumor size no difference
Gefitinib  anastrazole Metastatic II RCT TTP Ongoing
Gefitinib  anastrazole vs.
gefitinib  fulvestrant
Metastatic II RCT ORR Ongoing
Lapatinib
Lapatinib  tamoxifen Metastatic 2nd line II ORR/CBR Ongoing
Lapatinib  letrozole Metastatic III RCT TTP Ongoing
Lapatinib  fulvestrant Metastatic II RCT ORR/PK Ongoing
Trastuzumab
Trastuzumab  letrozole (176) Metastatic II ORR/TTP ORR 26%
TTP 5.5 months
Anastrazole vs. anastrazole
 trastuzumab (177)
Metastatic III ORR/TTP TTP 2.4 months vs. 4.8 months
ORR 6.8% vs. 20.3%
Trastuzumab  exemestane Metastatic II TTP Completed
RCT, Randomized controlled trial; ORR, objective response rate; CBR, clinical benefit rate; NS, not significant; Tam, tamoxifen; PK,
pharmacokinetics. Also see information in Johnston et al. (83).
a Only in EGFR-positive patients.
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sitivity and resistance in breast cancer. The genomic and
nongenomic activities of ER, as well as their complex inter-
play with many other growth factors and cellular kinase
pathways, influence tumor sensitivity to various types of
endocrine therapies. Although ER was first identified more
than 30 yr ago, we are still trying to clarify and understand
its multiple roles in normal physiology and in disease. In
breast cancer, there is convincing evidence that ER does not
act alone to stimulate tumor growth; rather, a complex in-
teracting network operates to ensure the viability of cancer
cells. Understanding this network will offer therapeutic ad-
vantages. The crosstalk between ER and growth factor re-
ceptor pathways is the cause of endocrine therapy resistance
in many patients. The combination of ER-targeted therapies
with growth factor receptor inhibitors or inhibitors of more
downstreamkinases is a novel strategy currently undergoing
more intensive clinical investigation. Future and ongoing
clinical trials will determine the true potential and applica-
bility of this combined therapeutic approach. Further clinical
trials are needed to evaluate various signaling elements from
the multiple networks that crosstalk with and modulate ER
activity as predictive markers for initial endocrine therapy.
In the future, a molecular profile of these different compo-
nents in a given patient’s tumor immediately before treat-
ment or at the time of disease progression after therapymight
permit the individualization of both the initial type of en-
docrine therapy and the appropriate signaling inhibitor
needed to block de novo or acquired resistance, a strategy that
should improve the treatment of breast cancer in the future.
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